Literature DB >> 12377403

Aging and panicogenic response to cholecystokinin tetrapeptide: an examination of the cholecystokinin system.

Alastair Flint1, Jacques Bradwejn, Franco Vaccarino, Jolanta Gutkowska, Roberta Palmour, Diana Koszycki.   

Abstract

Older age is associated with diminished symptomatic and cardiovascular response to the panicogenic agent cholecystokinin tetrapeptide (CCK-4). We hypothesized that circulating concentrations of endogenous CCK-4 and/or CCK-8 are increased in later life, possibly due to decreased enzymatic degradation, and that this is associated with desensitization of CCK-B receptors. The study group consisted of 20 healthy subjects aged 18-30 years and 20 healthy subjects aged 65-85 years. The two groups were compared on fasting basal plasma concentrations of CCK-4, sulfated CCK-8 (CCK-8s) and nonsulfated CCK-8 (CCK-8 ns), and on binding capacity of lymphocyte CCK-B receptors. Under single-blind (to subject) conditions, subjects were then administered an intravenous bolus of placebo, followed 50 min later by an intravenous bolus of 50 micro g of CCK-4. Plasma concentrations of total CCK (CCK(T)) were measured 2 min before and 2, 5, 10, and 15 min after each injection. Compared with younger subjects, older subjects had a significantly higher basal plasma concentration of CCK-8s and significantly diminished binding capacity of CCK-B receptors. Following injection of placebo, plasma CCK(T) concentrations did not significantly change from baseline in either age group, but the elderly had significantly higher concentrations than the young at 2, 5, and 10 min. Following injection of CCK-4, the plasma concentration of CCK(T) was highest at 2 min and declined after that. The elderly had significantly higher CCK(T) concentrations (ie. a slower decline in CCK(T)) than the young at 5, 10, and 15 min. These findings are consistent with our hypothesis and suggest that age-related changes in the CCK system could contribute to the diminished panicogenic response to exogenous CCK-4 in older persons.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12377403     DOI: 10.1016/S0893-133X(02)00330-5

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  7 in total

1.  'Acute shift in glutamate-concentrations following experimentally induced panic with cholecystokinin-tetrapeptide-a 3T-MRS study in healthy subjects'-a reply to the letter to the editor.

Authors:  Peter Zwanzger; Alexander Yassouridis; Bettina Pfleiderer
Journal:  Neuropsychopharmacology       Date:  2014-06-18       Impact factor: 7.853

2.  Comorbid anxiety in late-life depression: Relationship with remission and suicidal ideation on venlafaxine treatment.

Authors:  Yasmina M Saade; Ginger Nicol; Eric J Lenze; J Philip Miller; Michael Yingling; Julie Loebach Wetherell; Charles F Reynolds; Benoit H Mulsant
Journal:  Depress Anxiety       Date:  2019-11-04       Impact factor: 6.505

3.  Age-Dependent Effects of Chronic Stress on Zebrafish Behavior and Regeneration.

Authors:  Angie Henríquez Martínez; Laura C Ávila; María A Pulido; Yeferzon A Ardila; Veronica Akle; Natasha I Bloch
Journal:  Front Physiol       Date:  2022-04-29       Impact factor: 4.755

Review 4.  Diagnosis and management of panic disorder in older patients.

Authors:  Alastair J Flint; Nadine Gagnon
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

5.  Up-regulation of cholesterol absorption is a mechanism for cholecystokinin-induced hypercholesterolemia.

Authors:  LiChun Zhou; Hong Yang; Emmanuel U Okoro; Zhongmao Guo
Journal:  J Biol Chem       Date:  2014-04-01       Impact factor: 5.157

Review 6.  A lifespan view of anxiety disorders.

Authors:  Eric J Lenze; Julie Loebach Wetherell
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

7.  Cholecystokinin elevates mouse plasma lipids.

Authors:  Lichun Zhou; Hong Yang; Xinghua Lin; Emmanuel U Okoro; Zhongmao Guo
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.